Arcus Biosciences, Inc. - Common Stock (RCUS)
CUSIP: 03969F109
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 122,470,452
- Total 13F shares
- 99,735,332
- Share change
- +2,523,502
- Total reported value
- $811,386,525
- Put/Call ratio
- 5.2%
- Price per share
- $8.14
- Number of holders
- 181
- Value change
- +$23,005,595
- Number of buys
- 107
- Number of sells
- 75
Quarterly Holders Quick Answers
What is CUSIP 03969F109?
CUSIP 03969F109 identifies RCUS - Arcus Biosciences, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 03969F109:
Top shareholders of RCUS - Arcus Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. |
3/4/5
13F
|
10%+ Owner · Company |
26%
from 13F
|
31,424,760
|
$345,672,360 | — | 18 Feb 2025 | |
| BlackRock, Inc. |
13F
|
Company |
8.9%
|
10,867,091
|
$85,306,665 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5.5%
|
6,687,800
|
$52,499,230 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
4.2%
|
5,127,304
|
$40,249,336 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
3.6%
|
4,456,846
|
$34,986,238 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3%
|
3,696,479
|
$29,017,360 | — | 31 Mar 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
2.3%
|
2,867,097
|
$22,506,712 | — | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.1%
|
2,560,904
|
$20,103,096 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
1.4%
|
1,722,083
|
$13,519,592 | — | 31 Mar 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
1.3%
|
1,628,019
|
$12,779,000 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
1.3%
|
1,612,077
|
$12,654,804 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
1,389,232
|
$10,908,117 | — | 31 Mar 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.99%
|
1,215,629
|
$9,542,688 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.98%
|
1,194,622
|
$9,377,783 | — | 31 Mar 2025 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
0.93%
|
1,136,364
|
$8,920,457 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.88%
|
1,082,808
|
$8,500,043 | — | 31 Mar 2025 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
0.85%
|
1,037,776
|
$8,146,542 | — | 31 Mar 2025 | |
| Yasunori Kaneko |
3/4/5
|
Director |
—
mixed-class rows
|
990,555
mixed-class rows
|
$7,732,309 | — | 10 Jun 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.79%
|
972,157
|
$7,631,432 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.75%
|
914,208
|
$7,176,533 | — | 31 Mar 2025 | |
| Decheng Capital LLC |
13F
|
Company |
0.66%
|
808,789
|
$6,348,994 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.64%
|
787,080
|
$6,178,578 | — | 31 Mar 2025 | |
| Cutter Capital Management, LP |
13F
|
Company |
0.6%
|
731,818
|
$5,744,771 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.58%
|
714,002
|
$5,604,916 | — | 31 Mar 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.51%
|
625,126
|
$4,907,239 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.47%
|
570,042
|
$4,474,831 | — | 31 Mar 2025 | |
| Granahan Investment Management, LLC |
13F
|
Company |
0.39%
|
479,590
|
$3,764,782 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.33%
|
401,570
|
$3,152,325 | — | 31 Mar 2025 | |
| MACQUARIE GROUP LTD |
13F
|
Company |
0.31%
|
379,100
|
$2,976,000 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.31%
|
377,098
|
$2,960,219 | — | 31 Mar 2025 | |
| Hudson Bay Capital Management LP |
13F
|
Company |
0.3%
|
368,550
|
$2,893,118 | — | 31 Mar 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.27%
|
334,981
|
$2,629,601 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.24%
|
298,424
|
$2,342,628 | — | 31 Mar 2025 | |
| ALGERT GLOBAL LLC |
13F
|
Company |
0.22%
|
269,032
|
$2,112,000 | — | 31 Mar 2025 | |
| NORDEA INVESTMENT MANAGEMENT AB |
13F
|
Company |
0.22%
|
273,123
|
$2,081,198 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.21%
|
254,024
|
$1,994,087 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.21%
|
251,571
|
$1,974,833 | — | 31 Mar 2025 | |
| Cubist Systematic Strategies, LLC |
13F
|
Company |
0.2%
|
244,308
|
$1,917,819 | — | 31 Mar 2025 | |
| AXA S.A. |
13F
|
Company |
0.19%
|
231,608
|
$1,818,123 | — | 31 Mar 2025 | |
| Trexquant Investment LP |
13F
|
Company |
0.18%
|
215,366
|
$1,690,623 | — | 31 Mar 2025 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.17%
|
213,372
|
$1,674,970 | — | 31 Mar 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.17%
|
209,922
|
$1,647,888 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.17%
|
204,000
|
$1,601,400 | — | 31 Mar 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.16%
|
196,251
|
$1,541,000 | — | 31 Mar 2025 | |
| Legal & General Group Plc |
13F
|
Company |
0.15%
|
185,559
|
$1,456,637 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.15%
|
182,909
|
$1,435,812 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.15%
|
182,731
|
$1,434,439 | — | 31 Mar 2025 | |
| Nuyten Dimitry SA |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
201,218
mixed-class rows
|
$1,407,289 | — | 15 Dec 2024 | |
| Kathryn E. Falberg |
3/4/5
|
Director |
—
mixed-class rows
|
209,006
mixed-class rows
|
$1,386,132 | — | 10 Jun 2025 | |
| Campbell & CO Investment Adviser LLC |
13F
|
Company |
0.14%
|
165,474
|
$1,298,971 | — | 31 Mar 2025 |
Institutional Holders of Arcus Biosciences, Inc. - Common Stock (RCUS) as of Q2 2025
As of 30 Jun 2025,
Arcus Biosciences, Inc. - Common Stock (RCUS) was held by
181 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
99,735,332 shares.
The largest 10 holders included
GILEAD SCIENCES, INC., BlackRock, Inc., VANGUARD GROUP INC, Point72 Asset Management, L.P., Woodline Partners LP, SUVRETTA CAPITAL MANAGEMENT, LLC, STATE STREET CORP, FMR LLC, DIMENSIONAL FUND ADVISORS LP, and Siren, L.L.C..
This page lists
180
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
183
Q2 2025 holders
181
Holder diff
-2
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.